CAPR Stock Overview
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders.
Capricor Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.89|
|52 Week High||US$5.85|
|52 Week Low||US$2.56|
|1 Month Change||-3.17%|
|3 Month Change||55.24%|
|1 Year Change||21.64%|
|3 Year Change||63.54%|
|5 Year Change||-52.52%|
|Change since IPO||-88.36%|
Recent News & Updates
Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03
Capricor Therapeutics press release (NASDAQ:CAPR): Q2 GAAP EPS of -$0.29 misses by $0.03. As of June 30, 2022, the Company’s cash, cash equivalents and marketable securities totaled approximately $51.4 million, compared to approximately $34.9 million on December 31, 2021. No shares were sold under the Company’s at-the-market program in the second quarter of 2022. Shares -2.65%.
|CAPR||US Biotechs||US Market|
Return vs Industry: CAPR exceeded the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: CAPR exceeded the US Market which returned -10.2% over the past year.
|CAPR Average Weekly Movement||11.2%|
|Biotechs Industry Average Movement||12.6%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: CAPR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: CAPR's weekly volatility (11%) has been stable over the past year.
About the Company
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19.
Capricor Therapeutics, Inc. Fundamentals Summary
|CAPR fundamental statistics|
Is CAPR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CAPR income statement (TTM)|
|Cost of Revenue||US$16.61m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.03|
|Net Profit Margin||0.00%|
How did CAPR perform over the long term?See historical performance and comparison